Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat

Journal of Hypertension

Volumn 27, Issue 10, 2009, Pages 1980-1987

  Maillard, Marc P ^a   Tedjani, Andrée ^a   Perregaux, Christine ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Calcimimetics; Calcium sensing receptor; Enalapril; In vivo modulation; Isoproterenol; Juxtaglomerular cell; R 568; Rat; Renin

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CALCIUM CHLORIDE; CALCIUM SENSING RECEPTOR; CAPTOPRIL; FORSKOLIN; FUROSEMIDE; ISOPRENALINE; N [3 (2 CHLOROPHENYL)PROPYL]ALPHA METHYL 3 METHOXYBENZYLAMINE; PARATHYROID HORMONE; R 568; RENIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CELL ISOLATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG INFUSION; IN VITRO STUDY; IN VIVO STUDY; JUXTAGLOMERULAR CELL; MALE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN RELEASE;

EID: 70350463571     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832f0d22     Document Type: Article

References (28)

1. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 2007; 45:139-167.
2. Chattopadhyay N. Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int J Biochem Cell Biol 2000; 32:789-804.
3. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288:F253-F264.
4. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, Delmar EG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA1998; 95:4040-4045.
5. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135-141.
6. Lindberg JS, MoeSM, Goodman WG,CoburnJW,SpragueSM,Liu W, etal. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63:248-254.
7. Colloton M,Shatzen E, MillerG,Stehman-Breen C, WadaM, Lacey D, etal. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67:467-476.
8. Ogata H, Ritz E, Odoni G, Amann K, Orth SR. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14:959-967.
9. Odenwald T, Nakagawa K, Hadtstein C, Roesch F, Gohlke P, Ritz E, et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 2006; 17:655-662.
10. Rybczynska A, Boblewski K, Lehmann A, Orlewska C, Foks H, Drewnowska K, etal. Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats. Am J Hypertens 2005; 18:364-371.
11. Cunningham J, Danese M, Olson K, Klassen P, ChertowGM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:1793-1800.
12. Conigrave AD, Lok HC. Activation of renal calcium and water excretion by novel physiological and pharmacological activators of the calcium-sensing receptor. Clin Exp Pharmacol Physiol 2004; 31:368-371.
13. Ward DT, Riccardi D. Renal physiology of the extracellular calcium-sensing receptor. Pflugers Arch 2002; 445:169-176.
14. Ortiz-Capisano MC, Ortiz PA, Garvin JL, Harding P, Beierwaltes WH. Expression and function of the calcium-sensing receptor in juxtaglomerular cells. Hypertension 2007; 50:737-743.
15. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism 2. Pharmacol Ther 2006; 109:339-365.
16. Kurtz A, Pfeilschifter J, Bauer C. Is renin secretion governed by the calcium permeability of the juxtaglomerular cell membrane? Biochem Biophys Res Commun 1984; 124:359-366.
17. Wonneberger K, Scofield MA, Wangemann P. Evidence for a calcium-sensing receptor in the vascular smooth muscle cells of the spiral modiolar artery. J Membr Biol 2000; 175:203-212.
18. Nussberger J, Fluckiger JP, Hui KY, Evequoz D, Waeber B, Brunner HR. Angiotensin I and II disappear completely from circulating blood within 48h after binephrectomy: improved measurement of angiotensins in rat plasma. J Hypertens Suppl 1991; 9:S230-S231.
19. Ortiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Adenylyl cyclase isoform v mediates renin release from juxtaglomerular cells. Hypertension 2007; 49:618-624.
20. Ortiz-Capisano MC, Ortiz PA, Harding P, Garvin JL, Beierwaltes WH. Decreased intracellular calcium stimulates renin release via calcium-inhibitable adenylyl cyclase. Hypertension 2007; 49:162-169.
21. Geibel J, Sritharan K, Geibel R, Geibel P, Persing JS, Seeger A, et al. Calcium-sensing receptor abrogates secretagogue-induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction. Proc Natl Acad Sci U S A 2006; 103:9390-9397.
22. Fox J, Lowe SH, Petty BA, Nemeth EF. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999; 290:473-479.
23. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100:2977-2983.
24. Rybczynska A, Boblewski K, Lehmann A, Orlewska C, Foks H. Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats: dose dependency. Pharmacol Rep 2006; 58:533-539.
25. Richards AM, Espiner EA, Nicholls MG, Ikram H, Hamilton EJ, Maslowski AH. Hormone, calcium and blood pressure relationships in primary hyperparathyroidism. J Hypertens 1988; 6:747-752.
26. Salahudeen AK, Thomas TH, Sellars L, Tapster S, Keavey P, Farndon JR, et al. Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clin Sci (Lond) 1989; 76:289-296.
27. Valvo E, Bedogna V, Gammaro L, Casagrande P, Ortalda V, Maschio G. Systemic hemodynamic pattern in primary hyperparathyroidism and its changes after parathyroidectomy. Miner Electrolyte Metab 1991; 17:147-152.
28. Kamycheva E, Jorde R, Haug E, Sager G, Sundsfjord J. Effects of acute hypercalcaemia on blood pressure in subjects with and without parathyroid hormone secretion. Acta Physiol Scand 2005; 184:113-119.